Insys Therapeutics closed the most recent trading day at $4.81, moving +1.69% from the previous trading session. This change outpaced the S&P 500's 1.09% gain on the day. Elsewhere, the Dow gained 0.84%, while the tech-heavy Nasdaq added 1.42%.
Heading into today, shares of the specialty pharmaceutical company had lost 17.6% over the past month, lagging the Medical sector's gain of 1.58% and the S&P 500's gain of 1.18% in that time.
INSY will be looking to display strength as it nears its next earnings release. On that day, INSY is projected to report earnings of -$0.13 per share, which would represent year-over-year growth of 31.58%. Meanwhile, our latest consensus estimate is calling for revenue of $14.95 million, down 37.47% from the prior-year quarter.
INSY's full-year Zacks Consensus Estimates are calling for earnings of -$0.86 per share and revenue of $60.84 million. These results would represent year-over-year changes of +32.28% and -25.88%, respectively.
Any recent changes to analyst estimates for INSY should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 44.86% lower. INSY is holding a Zacks Rank of #4 (Sell) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 76, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Insys Therapeutics (INSY) Outpaces Stock Market Gains: What You Should Know
Insys Therapeutics closed the most recent trading day at $4.81, moving +1.69% from the previous trading session. This change outpaced the S&P 500's 1.09% gain on the day. Elsewhere, the Dow gained 0.84%, while the tech-heavy Nasdaq added 1.42%.
Heading into today, shares of the specialty pharmaceutical company had lost 17.6% over the past month, lagging the Medical sector's gain of 1.58% and the S&P 500's gain of 1.18% in that time.
INSY will be looking to display strength as it nears its next earnings release. On that day, INSY is projected to report earnings of -$0.13 per share, which would represent year-over-year growth of 31.58%. Meanwhile, our latest consensus estimate is calling for revenue of $14.95 million, down 37.47% from the prior-year quarter.
INSY's full-year Zacks Consensus Estimates are calling for earnings of -$0.86 per share and revenue of $60.84 million. These results would represent year-over-year changes of +32.28% and -25.88%, respectively.
Any recent changes to analyst estimates for INSY should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 44.86% lower. INSY is holding a Zacks Rank of #4 (Sell) right now.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 76, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.